Bipolar disorder: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 0
• BDNF 0
• NMDA 1
• SGLT2 1
• PI3K 0
• AQP4 0
• PCSK9 0
• PPAR 0
• TNF 0
• AKT 0
• BRD4 0
• G6PD 0
• IGF1R 0
• IL-1 0
• IL-17 0
• IL-6 0
• MAPT 0
• NLRP3 0
• NRF2 0
• SIRT1 0
• TFEB 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  The cerebellum: a transdiagnostic personalised target for neuromodulation in psychiatry (CLOVIS)

  Universite Paris Xii Val de Marne· Creteil, France· EU contribution €1,499,500· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Callyope Copilot: Speech Foundation Model for Transdiagnostic Mental Health Assessment & Relapse Mitigation (CALLYOPECOPILOT)

  Callyope· Neuilly sur Seine, France· EU contribution €2,498,053· until May 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Personalized Genetic Risk Profile: A New Tool to Guide Prevention of Serious Mental Illness (PersonalRiskProfile)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €1,499,891· until Dec 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synaptic signatures: Understanding thalamocortical circuit specification and disease vulnerability (ThalamoLinkIT)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Mar 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms (SYNAPSING)

  Institut de Recerca de L'hospital de la Santa Creu I Sant Pau Fundacion· Barcelona, Spain· EU contribution €6,999,922· until Dec 2029· 9 countries

5 of 10 running projects, newest first. Listed amounts together: €29.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 52
• CRISPR-Cas Systems 2
• Gene Expression Profiling 23
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 17
• Metabolomics 8
• Mass Spectrometry 3
• Immunohistochemistry 1
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 190
• Machine Learning 59
• Deep Learning 9
• Cohort Studies 96
• Genome-Wide Association Study 107

• MS-based metabolic profiling in serum for bipolar disorder.

  Metab Brain Dis, Jul 2026

• Copper and Zinc as Potential Biomarkers of Mood Disorders and Pandemic Syndrome.

  Molecules, Dec 2021

• Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species.

  J Psychiatr Res, Jan 2010

See which targets of this disease your abstract mentions, and go to the people working on them.